Ichthyosis Clinical Trial
— e-ETPichtyoseOfficial title:
Evaluation of the Feasibility and Effect of Therapeutic Education Sessions Using an Internet Application in Hereditary Ichthyosis
Verified date | April 2024 |
Source | University Hospital, Toulouse |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main purpose is to evaluate the feasibility (global use) of a therapeutic patient education program using a specific web application in patients with hereditary ichthyosis.
Status | Completed |
Enrollment | 42 |
Est. completion date | February 21, 2023 |
Est. primary completion date | February 21, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 60 Years |
Eligibility | Inclusion Criteria: - Patient with hereditary ichthyosis, according to the classification established during the 2009 consensus conference - Who has given his informed consent form - Who is affiliated to a social security system Exclusion Criteria: - Patient who has already participated in a therapeutic patient education program for the hereditary ichthyosis - Unable to connect or use a computer tool - Impossibility to be present at the only face-to-face session - Patient who is not available for the collective educational session - Patient with little or no motivation to follow a therapeutic patient education program (motivation evaluated by the educational team by phone call before inclusion) - Patient not mastering the French language - Person under legal protection (guardianship, curators or safeguard of justice) |
Country | Name | City | State |
---|---|---|---|
France | CHU Toulouse, Hôpital Larrey | Toulouse |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Toulouse |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Global use | percentage of patients who have used the "WebIchtyose" application for at least 8 hours during 6 months | 6 months | |
Secondary | Fractional use in each domain (educational sessions) | "WebIchtyose" application use time by the patient for group and individual educational sessions | 6 months | |
Secondary | Fractional use in each domain (continuous educational follow-up) | "WebIchtyose" application use time by the patient for the continuous educational follow-up | 6 months | |
Secondary | Fractional use in each domain (consultation) | "WebIchtyose" application use time by the patient for the consultation of the "Frequently Asked Questions" area and of patient information documents made available on the application | 6 months | |
Secondary | Fractional use in each domain (questionnaires) | "WebIchtyose" application use time by the patient for the filling of the questionnaires | 6 months | |
Secondary | Fractional use in each domain | "WebIchtyose" application use time by the patient for group and individual educational sessions, the continuous educational follow-up, the consultation of the "Frequently Asked Questions" area and of patient information documents made available on the application | 6 months | |
Secondary | Difficulty of individual application registration | Difficulty of registration questionnaire completed for each patient jointly by the patient and the educational team at the end of the face-to-face inclusion visit | Baseline | |
Secondary | Difficulties of use in everyday life by the patient | Questionnaire completed for each patient jointly by the patient at the end of the program | 6 months | |
Secondary | Number of exchanges | Number of exchanges necessary between the educational team and the patient to set a date for the conduct of the individual educational sessions | 3 months and 5 months | |
Secondary | Response time | Response time of the educational team following a request from the patient as part of the educational follow-up | 6 months | |
Secondary | Number of relaunches | How many times the nurse relaunches the patient to obtain the assessment questionnaires | 2 months, 4 months and 6 months | |
Secondary | Number of non-received questionnaires | Number of non-received questionnaires after relaunch | 2 months, 4 months and 6 months | |
Secondary | Number of lost to follow-up patients | Number of lost to follow-up patients | 9 months | |
Secondary | Patient acceptability | Acceptability questionnaire to be completed by the patient | 6 months | |
Secondary | Educational team acceptability | Acceptability questionnaire to be completed by each member of the educational team | 6 months | |
Secondary | Attractiveness | Application attractiveness questionnaire completed by the patient | 6 months | |
Secondary | Quality of life before and after treatment | Quality of life questionnaire for hereditary ichthyosis (IQoL-32) | Inclusion, 6 months and 9 months | |
Secondary | Self-assessment of cutaneous severity | Self-assessment of cutaneous severity according to an analogic visual scale for pain, pruritus, erythema, squama | Inclusion and 6 months | |
Secondary | Knowledge about disease and treatments | Questionnaire of knowledge about disease and treatments | Inclusion and 6 months | |
Secondary | Self-care skills | Questionnaire of self-care skills | Inclusion and 6 months | |
Secondary | Self-esteem | Questionnaire about self-esteem: Rosenberg scale. For each item of the questionnaire, the modality answers are : 1 (totally disagree), 2 (quite disagree), 3 (quite agree) and 4 (totally disagree). The total score (/ 40) is calculated by adding the scores obtained for each item. | Inclusion and 6 months | |
Secondary | Coping scale | Coping with health injuries and problem (Endler 1998). For each item of the questionnaire, the modality answers are: 1 (not at all), 2 (a little), 3 (moderately), 4 (often) and 5 (a lot).The total score (/ 160) is calculated by adding the scores obtained for each item. | Inclusion and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03051347 -
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
|
N/A | |
Completed |
NCT00004690 -
Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis
|
Phase 3 | |
Completed |
NCT00074685 -
National Registry for Ichthyosis and Related Disorders
|
||
Completed |
NCT03796052 -
Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
|
N/A | |
Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
Active, not recruiting |
NCT05295732 -
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
|
Phase 3 | |
Terminated |
NCT02655861 -
A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
|
||
Recruiting |
NCT03464994 -
Ophthalmological Abnormalities in Hereditary Ichthyosis (ICHTYO-KERATO)
|
N/A | |
Recruiting |
NCT03417856 -
Defining the Skin and Blood Biomarkers of Ichthyosis
|
||
Terminated |
NCT04697056 -
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
|
Phase 2 | |
Recruiting |
NCT06330350 -
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
|
||
Enrolling by invitation |
NCT06330324 -
Reproductive Options in Inherited Skin Diseases
|
||
Completed |
NCT03041038 -
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
|
Phase 2 | |
Not yet recruiting |
NCT06362447 -
Efficacy of Injectable Gentamicin in Hereditary Ichthyosis
|
Phase 2 | |
Active, not recruiting |
NCT04549792 -
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
|
Early Phase 1 |